TOTAL: $350.551M | |||||
Company (Location) |
Type Of Financing |
Number Of Shares, Units Or Warrants (M) |
Amount Raised |
Investors; Placement Agents; Details |
Date |
Allon Therapeutics Inc. (Vancouver, British Columbia) |
Private placement |
40U |
C$10 ($9.98) |
Allon plans to raise $9.98M in the placement of equity units and subscription receipts, both priced at C25 cents each, for a total of about 40M units, each sonsisting of one common share and one-half of one common share purchase warrant |
4/17/12 |
Bioniche Life Sciences Inc. (Belleville, Ont.) |
Loan |
N/A |
$20 |
Bioniche closed a $20M financing from investment funds managed by Capital Royalty LP; it involves a five-year term loan and a 2% royalty interest on product sales revenues for the term of the loan |
4/12/12 |
BioRestorative Therapies Inc. (Jupiter, Fla.) |
Debt and equity financing |
22S and 25.5W |
$2.1 |
BioRestorative raised $1.6M in debt and $500,000 in equity in multiple financing rounds in 2012 |
4/11/12 |
Cytos Biotechnology Ltd. (Zurich, Switzerland) |
Rights issue |
2.67S |
CHF5 ($4.16) |
Cytos is raising $4.16M through a rights issue of up to 2.67M shares |
4/24/12 |
DARA BioSciences Inc. (Raleigh, N.C.) |
Private placement of preferred stock and warrants |
W for 10.1S |
$10.1 |
DARA raised $10.1M by placing Series B-2 convertible preferred stock, five-year warrants to purchase up to 5.05M shares of common stock at $1 per share, and five-year warrants to purchase up to 5.05M shares at $1.25 each; Ladenburg Thalmann & Co. Inc. acted as exclusive placement agent for the offering |
4/10/12 |
Derma Sciences Inc. (Princeton, N.J.) |
Registered direct offering |
2.125S |
$19.66 |
Derma priced a direct offering of 2.125M shares of common stock at $9.25 per share; Piper Jaffray & Co. is acting as sole underwriter |
4/3/12 |
Nile Therapeutics Inc. (San Mateo, Calif.) |
Private placement of common stock and warrants |
3.35S |
$1.34 |
Nile will sell 3.35M shares of common stock at $0.40 for gross proceeds of $1.34M; Roth Capital Partners LLC was sole placement agent |
4/3/12 |
Oculus Innovative Sciences Inc. (Petaluma, Calif.) |
Private placement |
2.4S and W for 3.5S |
$3.1 |
Oculus sold to an institutional investor 1,000 shares of new Series A convertible preferred stock for $1,000 per share, plus 2.4M shares at 90 cents apiece, and 2.5-year warrant to buy up to about 3.5M shares of common stock at $1.18 per share |
4/25/12 |
PharmAthene Inc. (Annapolis, Md.) |
Senior secured credit facility |
N/A |
$7.5 |
PharmAthene secured $7.5M in credit facilities from GE Capital, Healthcare Financial Services consisting of a $2.5M term loan and a revolving line of credit of up to $5M |
4/4/12 |
PolyMedix Inc. (Radnor, Pa.) |
Loan |
N/A |
$6.3 |
PolyMedix secured a $12M loan from MidCap Financial LLC; it used $5.7M to pay off an existing debt facility and the rest is for general working capital |
4/11/12 |
ProMetic Life Sciences Inc. (Laval, Quebec) |
Private placement |
2.9S and 0.455W |
$0.125 |
ProMetic raised $125,000 by placing 2.9M shares and 454,545 warrants with board member Benjamin Wygodny |
4/30/12 |
ReNeuron Group plc (Guildford, UK) |
Private offering |
134S |
£5.4 ($8.6) |
ReNeuron received commitments from new and existing shareholders for a private offering of 134M shares at 4 pence each |
4/4/12 |
RepliCel Life Sciences Inc. (Vancouver, British Columbia) |
Private placement of units |
0.876U; 0.503U; 0.43U |
$1.3; $0.754; $0.645 |
RepliCel raised $1.3M in the placement of 876,042 units priced at $1.50 apiece; it later raised $754,000 in a placement of 502,667 units priced at $1.50 each, as well as another $645,000 in a placement of 430,033 shares at the same price |
4/2/12; 4/20/12; 4/24/12 |
Sernova Corp. (London, Ont.) |
Private placement of units |
20U |
C$3.6 ($3.6) |
Sernova raised $3.6M through the private placement of 20M units |
4/4/12 |
Summit Corp plc (Oxford, UK) |
Private placement of common stock |
166.7S |
£5 ($7.9) |
Summit raised $7.9M by issuing 166.7M shares at 3 pence each to institutional investors and directors; the offering was underwritten by Singer Capital Markets Ltd., and Hybridan LLP acted as joint broker |
4/5/12 |
Sunesis Pharmaceuticals Inc. (San Francisco) |
Royalty sale |
N/A |
$25 |
Sunesis received $25M from Royalty Pharma for a royalty on future worldwide sales of acute myeloid leukemia drug vosaroxin |
4/2/12 |
Theravance Inc. (South San Francisco) |
Equity investment |
10S |
$212.887 |
Theravance received an investment from GlaxoSmithKline plc for a total investment of $212.887M |
4/3/12 |
Titan Pharmaceuticals Inc. (South San Francisco) |
Registered direct offering |
6.5S and W for 13.04S |
$5.5 |
Titan is raising $5.5M through the offering of 6.5M shares for 85 cents each and warrants for an additional 13.04M shares; Rodman & Renshaw LLC acted as the placement agent |
4/11/12 |
|
Notes: This chart does not include real estate or manufacturing plant financings, or debt deals done to replace existing debt. Loan money is included in the total only when it is drawn down, if disclosed. Currency conversions are based on exchange rates at the time of the deal. The date indicated refers to the BioWorld Today issue in which the news item can be found. N/A = Not applicable; ND = Not disclosed. | |||||